Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer

Coombes, R C; Badman, P D; Lozano-Kuehne, J P; Liu, X; Macpherson, I R; Zubairi, I; Baird, R D; Rosenfeld, N; Garcia-Corbacho, J; Cresti, N; Plummer, R; Armstrong, A; Allerton, R; Landers, D; Nicholas, H; McLellan, L; Lim, A; Mouliere, F; Pardo, OE; Ferguson, V; Seckl, MJ

Affiliation

The Dudley Group NHS Foundation Trust

Publication date

2023-01-17

Metadata

Show full item record

Abstract

No abstract available

Citation

Nat CoCoombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, Baird RD, Rosenfeld N, Garcia-Corbacho J, Cresti N, Plummer R, Armstrong A, Allerton R, Landers D, Nicholas H, McLellan L, Lim A, Mouliere F, Pardo OE, Ferguson V, Seckl MJ. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nat Commun. 2023 Jan 17;14(1):260. doi: 10.1038/s41467-023-35969-4. Erratum for: Nat Commun. 2022 Jun 10;13(1):3246. doi: 10.1038/s41467-022-30666-0mmun. 2023 Jan 17;14(1):260. doi: 10.1038/s41467-023-35969-4.